Browsing ICR Divisions by author "Arthur, Amani"
Now showing items 1-8 of 8
-
Characterisation of a Novel Cell Line (ICR-SS-1) Established from a Patient-Derived Xenograft of Synovial Sarcoma.
Kerrison, WGJ; Ning, J; Krasny, L; Arthur, A; Guljar, N; et al. (MDPI, 2022-08-04)Synovial sarcoma is a rare translocation-driven cancer with poor survival outcomes, particularly in the advanced setting. Previous synovial sarcoma preclinical studies have relied on a small panel of cell lines which suffer ... -
Proteomic Profiling Identifies Co-Regulated Expression of Splicing Factors as a Characteristic Feature of Intravenous Leiomyomatosis.
Krasny, L; Wilding, CP; Perkins, E; Arthur, A; Guljar, N; et al. (MDPI, 2022-06-13)Intravenous leiomyomatosis (IVLM) is a rare benign smooth muscle tumour that is characterised by intravenous growth in the uterine and pelvic veins. Previous DNA copy number and transcriptomic studies have shown that IVLM ... -
Proteomic profiling of soft tissue sarcomas with SWATH mass spectrometry.
Milighetti, M; Krasny, L; Lee, ATJ; Morani, G; Szecsei, C; et al. (ELSEVIER, 2021-06-15)Soft tissue sarcomas (STS) are a group of rare and heterogeneous cancers. While large-scale genomic and epigenomic profiling of STS have been undertaken, proteomic analysis has thus far been limited. Here we utilise ... -
Radiomic Features From Diffusion-Weighted MRI of Retroperitoneal Soft-Tissue Sarcomas Are Repeatable and Exhibit Change After Radiotherapy.
Thrussell, I; Winfield, JM; Orton, MR; Miah, AB; Zaidi, SH; et al. (FRONTIERS MEDIA SA, 2022-07-18)BACKGROUND: Size-based assessments are inaccurate indicators of tumor response in soft-tissue sarcoma (STS), motivating the requirement for new response imaging biomarkers for this rare and heterogeneous disease. In this ... -
Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer.
Pacini, L; Jenks, AD; Vyse, S; Wilding, CP; Arthur, A; et al. (DOVE MEDICAL PRESS LTD, 2021-03-08)Insertion mutations in exon 20 (Ex20ins) of the epidermal growth factor receptor (EGFR) gene are the largest class of EGFR mutations in non-small cell lung cancer (NSCLC) for which there are currently no approved targeted ... -
Telemedicine During the COVID-19 Pandemic: Impact on Care for Rare Cancers.
Smrke, A; Younger, E; Wilson, R; Husson, O; Farag, S; et al. (AMER SOC CLINICAL ONCOLOGY, 2020-06-01)PURPOSE: Many patients with cancer, often those with rare cancers such as sarcomas, travel long distances to access expert care. The COVID-19 pandemic necessitated widespread changes in delivery of cancer care, including ... -
The proteomic landscape of soft tissue sarcomas.
Burns, J; Wilding, CP; Krasny, L; Zhu, X; Chadha, M; et al. (NATURE PORTFOLIO, 2023-06-29)Soft tissue sarcomas (STS) are rare and diverse mesenchymal cancers with limited treatment options. Here we undertake comprehensive proteomic profiling of tumour specimens from 321 STS patients representing 11 histological ... -
Virtual Biopsy in Soft Tissue Sarcoma. How Close Are We?
Arthur, A; Johnston, EW; Winfield, JM; Blackledge, MD; Jones, RL; et al. (FRONTIERS MEDIA SA, 2022-07-01)A shift in radiology to a data-driven specialty has been unlocked by synergistic developments in imaging biomarkers (IB) and computational science. This is advancing the capability to deliver "virtual biopsies" within ...